This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on september 18, 2020.Upon further investigation of the reported event, the following information is new and/or changed: h6 (identification of evaluation codes 10, 3331, 213, 67) method code #1: 10 - testing of actual/suspected device.Method code #2: 3331 - analysis of production records.Results code: 213 - no device problem found.Conclusions code: 67 - no problem detected.The affected sample was inspected upon receipt and no obvious anomaly that could lead to a poor pressure holding performance.The blood channel was filled with physiological saline solution, and then an air pressure of 2kgf/cm2 was applied and no leak occurred.The sample was set into a circuit with tubing, and then physiologic saline was circulated with each flow while the pressure drop was measured and no difference in the pressure drop was observed.As a result it was confirmed that the sample is within the factory's standard with no abnormality confirmed.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|